Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Dec 04, 2017 12:03pm

94 Views

Post# 27085436

RE:RE:Couple of videos potentially worth your time

As of Sept 2014, Share price was roughly 0.50 and roughly 46 Million shares.
That gave it a market cap of roughly 23 Million

Since then we bought Citagenix for 10 Million, we did a small Phase 2 trial with success and we are doing a mid size Phase 2 trail with no negative news thus far.

Our current market cap is ~23 Million.
So we are valued about the same as we were 3 years ago.

My argument is that we are much further ahead now then we were then and should be valued,more then then.
I agree we are very undervalued in its current state. Let alone future resutls.

I don't know what our current share price should be, but its well north of it's current position.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading